Phenominer Database Results (32 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa+/+/Slc heart ventricle septal wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 10 0.18 cm 0.0 0.01 echocardiography 0.0 0 101784 2641
SS.ZUC-Leprfa+/+/Slc E/A wave ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 10 1.72 null 0.06 0.19 echocardiography 0.0 0 101814 2641
SS.ZUC-Leprfa+/+/Slc E wave deceleration time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 10 38.2 ms 1.45 4.59 echocardiography 0.0 0 101818 2641
SS.ZUC-Leprfa+/+/Slc serum triglyceride level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 10 87.0 mg/dl 4.08 12.9 serum triglyceride analysis 0.0 0 101850 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to body weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 10 0.39 ml/min/100g 0.04 0.13 serum creatinine analysis 0.0 0 101878 2641
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 10 296.35 mg/mm 14.18 44.84 post excision weight measurement 0.0 0 liv/tl 101764 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle relative wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 10 45.0 % 2.0 6.32 echocardiography 0.0 0 101802 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 10 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101760 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle fractional shortening everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 10 35.33 % 1.87 5.91 echocardiography 0.0 0 101806 2641
SS.ZUC-Leprfa+/+/Slc heart isovolumetric relaxation time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 10 31.43 ms 1.47 4.65 echocardiography 0.0 0 101822 2641
SS.ZUC-Leprfa+/+/Slc blood aspartate aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 10 59.0 U/l 7.42 23.46 automated blood analysis 0.0 0 101858 2641
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 10 0.34 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101756 2641
SS.ZUC-Leprfa+/+/Slc single kidney weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 10 29.2 g/cm 1.03 3.26 post excision weight measurement 0.0 0 101768 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to total kidney weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 10 0.47 ml/min/g 0.05 0.16 serum creatinine analysis 0.0 0 101882 2641
SS.ZUC-Leprfa+/+/Slc serum free fatty acids level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 10 15.09 mmol/l 1.17 3.69 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101854 2641
SS.ZUC-Leprfa+/+/Slc urine total protein level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 10 4.79 mg/ml 1.47 4.64 urine protein analysis 0.0 0 101870 2641
SS.ZUC-Leprfa+/+/Slc epididymal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 10 1.29 g/cm 0.03 0.11 post excision weight measurement 0.0 0 ef/tl 101776 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle end-diastolic diameter everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 10 7.65 mm 0.12 0.38 echocardiography 0.0 0 101788 2641
SS.ZUC-Leprfa+/+/Slc calculated heart left ventricle weight everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 10 962.28 mg 30.76 97.27 echocardiography 0.0 0 101796 2641
SS.ZUC-Leprfa+/+/Slc pancreas weight to tibia length everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 10 39.44 mg/mm 1.95 6.17 post excision weight measurement 0.0 0 p/tl 101834 2641
SS.ZUC-Leprfa+/+/Slc serum creatinine level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 10 0.34 mg/dl 0.01 0.03 serum creatinine analysis 0.0 0 101874 2641
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 10 113.78 mg/mm 2.71 8.57 post excision weight measurement 0.0 0 rf/tl 101772 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 10 196.56 mg/mm 8.21 25.96 post excision weight measurement 0.0 0 if/tl 101780 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 5 0.6 mmHg/mm 0.05 0.11 echocardiography 0.0 0 lvedp/lvdd 101830 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle posterior wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 10 1.7 mm 0.06 0.19 echocardiography 0.0 0 101792 2641
SS.ZUC-Leprfa+/+/Slc ejection fraction everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 10 72.2 % 2.34 7.4 echocardiography 0.0 0 101810 2641
SS.ZUC-Leprfa+/+/Slc blood high density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 10 22.5 mg/dl 2.27 7.18 blood cholesterol analysis 0.0 0 101842 2641
SS.ZUC-Leprfa+/+/Slc serum urea nitrogen level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 10 23.55 mg/dl 0.85 2.69 serum urea nitrogen analysis 0.0 0 101866 2641
SS.ZUC-Leprfa+/+/Slc time constant of left ventricular pressure decay everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 10 29.01 ms 2.59 8.19 echocardiography 0.0 0 101826 2641
SS.ZUC-Leprfa+/+/Slc blood total cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 10 11.83 mg/dl 8.11 25.65 blood cholesterol analysis 0.0 0 101838 2641
SS.ZUC-Leprfa+/+/Slc blood low density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 10 24.0 mg/dl 0.94 2.97 blood cholesterol analysis 0.0 0 101846 2641
SS.ZUC-Leprfa+/+/Slc blood alanine aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 10 25.5 U/l 1.15 3.64 automated blood analysis 0.0 0 101862 2641